Pittenger & Anderson Inc. Has $12.93 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Pittenger & Anderson Inc. decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,474 shares of the company’s stock after selling 2,002 shares during the period. Pittenger & Anderson Inc.’s holdings in Johnson & Johnson were worth $12,927,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Eley Financial Management Inc boosted its position in shares of Johnson & Johnson by 1.0% in the 4th quarter. Eley Financial Management Inc now owns 19,502 shares of the company’s stock worth $3,057,000 after purchasing an additional 188 shares during the last quarter. Lyell Wealth Management LP grew its position in shares of Johnson & Johnson by 68.9% during the 4th quarter. Lyell Wealth Management LP now owns 7,596 shares of the company’s stock worth $1,191,000 after buying an additional 3,099 shares during the period. Disciplined Equity Management Inc. bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $45,000. GHE LLC boosted its stake in Johnson & Johnson by 1.1% during the 4th quarter. GHE LLC now owns 12,124 shares of the company’s stock worth $1,900,000 after acquiring an additional 130 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. grew its holdings in Johnson & Johnson by 2.4% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 56,732 shares of the company’s stock valued at $8,892,000 after purchasing an additional 1,343 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on JNJ shares. Raymond James lifted their price target on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Bank of America decreased their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price objective for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Monday, April 15th. Finally, Morgan Stanley cut their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $175.86.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $146.84 on Tuesday. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. The firm has a fifty day simple moving average of $155.07 and a 200 day simple moving average of $155.23. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The stock has a market capitalization of $353.85 billion, a PE ratio of 9.15, a P/E/G ratio of 2.41 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The company had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. During the same period in the previous year, the business earned $2.68 EPS. Johnson & Johnson’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, research analysts expect that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be issued a dividend of $1.24 per share. The ex-dividend date is Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.38%. Johnson & Johnson’s payout ratio is presently 29.68%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.